TABLE 3.
Treatment response of patients with limited stage by lipocalin‐2, NLR, and PMI.
| Treatment response | Lipocalin‐2 alone | Lipocalin‐2 and NLR | Lipocalin‐2 and PMI | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low lipocalin‐2 (n = 35) | High lipocalin‐2 (n = 37) | p‐value | Group 1 (n = 25) | Group 2 (n = 33) | Group 3 (n = 14) | p‐value | Group 1 (n = 32) | Group 2 (n = 31) | Group 3 (n = 9) | p‐value | |
| CR | 12 (34.3) | 7 (18.9) | 0.035 a | 12 (48.0) | 6 (18.2) | 1 (7.1) | 0.001 b | 11 (34.4) | 8 (25.8) | 0 | 0.002 b |
| PR | 22 (62.9) | 24 (64.9) | 12 (48.0) | 24 (72.7) | 10 (71.4) | 20 (62.5) | 22 (71.0) | 4 (44.4) | |||
| SD, PD, or not evaluated | 1 (2.9) | 6 (16.2) | 1 (4.0) | 3 (9.1) | 3 (21.4) | 1 (3.1) | 1 (3.2) | 5 (55.6) | |||
| Objective response rate (CR + PR) | 34 (97.1) | 31 (83.8) | 0.108 | 24 (96.0) | 30 (90.9) | 11 (78.6) | 0.090 a | 31 (96.9) | 30 (96.8) | 4 (44.4) | <0.001 a |
Note: The variables are presented as numbers (%).
Abbreviations: CR, complete response; NLR, neutrophil‐lymphocyte ratio; PD, progressive disease; PMI, pectoralis muscle index; PR, partial response; SD, stable disease.
a
Cochrane‐Armitage trend test.
b
Cuzick's trend test.